IRS extends the research credit claim transition period to Jan. 10, 2026

by RSM US LLP | Nov 26, 2024

Insights We are proud to be named a West Coast Regional Leader for 2024 < Back to Insights and Resources IRS extends the research credit claim transition period to Jan. 10, 2026ARTICLE | November 26, 2024Authored by RSM US LLPExecutive summaryThe IRS requires...

How life sciences companies can prepare for tax changes under Trump in 2025

by RSM US LLP | Nov 15, 2024

Insights We are proud to be named a West Coast Regional Leader for 2024 < Back to Insights and Resources How life sciences companies can prepare for tax changes under Trump in 2025ARTICLE | November 15, 2024Authored by RSM US LLPExecutive summary: Life sciences...

Maximizing value through compliance: Strategic insights for life sciences leaders

by RSM US LLP | Nov 14, 2024

Insights We are proud to be named a West Coast Regional Leader for 2024 < Back to Insights and Resources Maximizing value through compliance: Strategic insights for life sciences leadersARTICLE | November 14, 2024Authored by RSM US LLPFor growing life sciences...

Biopharmas: Spending too much on trials, tariffs and indirect taxes?

by RSM US LLP | Apr 9, 2024

Insights We are proud to be named a West Coast Regional Leader for 2024 < Back to Insights and Resources Biopharmas: Spending too much on trials, tariffs and indirect taxes?ARTICLE | April 09, 2024Authored by RSM US LLPBiopharmaceutical companies contend with high...

With new regulations, medtech companies should assess cyber risk

by RSM US LLP | Jan 24, 2024

Insights We are proud to be named a West Coast Regional Leader for 2024 < Back to Insights and Resources With new regulations, medtech companies should assess cyber riskARTICLE | January 24, 2024Authored by RSM US LLPMedtech companies are increasingly grappling...